Skip to main content

Table 3 The league table for OS estimates interventions according to their relative effects in first part network analysis

From: Second-line treatment strategy for urothelial cancer patients who progress or are unfit for cisplatin therapy: a network meta-analysis

Apatorsen+Taxane (66.6%)a,b        
− 0.02 (− 0.41,0.37)Atezolizumab (71.1%)       
0.22 (−0.35,0.80)0.24 (− 0.27,0.76)Icrucumab+Taxane (36.3%)      
0.47 (−0.05,0.99)0.49 (0.03,0.95)b0.25 (−0.38,0.87)Pazopanib (11.5%)     
−0.14 (− 0.53,0.25)−0.12 (− 0.38,0.14)−0.36 (− 0.88,0.15)− 0.61 (− 1.07,-0.15)Pemborlizumab (87.5%)    
− 0.09 (− 0.67,0.50)−0.07 (− 0.60,0.46)−0.31 (− 0.99,0.37)−0.56 (− 1.19,0.08)0.05 (− 0.48,0.58)Ramucirumab+Taxane (74.6%)   
0.22 (−0.10,0.55)0.24 (0.03,0.46)−0.00 (− 0.47,0.47)−0.25 (− 0.66,0.16)0.36 (0.15,0.57)0.31 (− 0.18,0.80)Taxane (31.6%)  
0.41 (−0.11,0.93)0.43 (−0.02,0.89)0.19 (− 0.43,0.81)−0.06 (− 0.63,0.52)0.55 (0.10,1.01)0.50 (− 0.13,1.13)0.19 (− 0.21,0.59)Vandetanib+Taxane (16.2%) 
0.07 (− 0.34,0.48)0.09 (− 0.11,0.30)−0.15 (− 0.68,0.38)−0.40 (− 0.88,0.08)0.21 (− 0.04,0.46)0.16 (− 0.39,0.71)−0.15 (− 0.40,0.10)−0.34 (− 0.82,0.13)Vinflunine (54.6%)
  1. OS Overall Survival
  2. aThe SUCRA probabilities are performed in brackets
  3. bBold font means significant different